All In Biotech

Drug Trial Radar · NCT04666688

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 as a Single Agent and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

44

Actual

Start

Dec 11, 2020

Primary completion

Dec 12, 2024

Study completion Dec 12, 2024

Sponsor

Lead sponsor
PureTechIndustry
Sponsor type
Industry
First posted
Dec 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or tislelizumab in Patients with Metastatic Solid Tumors

Conditions

  • Metastatic Cancer
  • Solid Tumor
  • Head and Neck Cancer

Interventions

  • LYT-200Drug

    monoclonal antibody (mAb), targeting galectin-9 protein

  • TislelizumabDrug

    anti-PD-1 monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Incidence of Treatment-Emergent Adverse Events [Safety]Time frame: approximately 1 year
  2. Part 1: Incidence of Dose Limiting Toxicities [Tolerability]Time frame: approximately 1 year

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA

    Los Angeles, California

  • University of Colorado Hospital

    Denver, Colorado

  • Sarah Cannon Research Institute at Health One

    Denver, Colorado

  • Sarah Cannon Research Institute, Florida Cancer Specialists

    Sarasota, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • South Texas Accelerated Research Therapeutics

    Grand Rapids, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Columbia University

    New York, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Sarah Cannon Research Institute, Tennessee Oncology

    Nashville, Tennessee

  • University of Texas, M.D. Anderson Cancer Center

    Houston, Texas

  • South Texas Accelerated Research Therapeutics

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.